ES2819217T3 - Conjugados de polímeros iónicos dipolares y factor VIII - Google Patents

Conjugados de polímeros iónicos dipolares y factor VIII Download PDF

Info

Publication number
ES2819217T3
ES2819217T3 ES14841835T ES14841835T ES2819217T3 ES 2819217 T3 ES2819217 T3 ES 2819217T3 ES 14841835 T ES14841835 T ES 14841835T ES 14841835 T ES14841835 T ES 14841835T ES 2819217 T3 ES2819217 T3 ES 2819217T3
Authority
ES
Spain
Prior art keywords
polymer
group
fviii
initiator
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14841835T
Other languages
English (en)
Spanish (es)
Inventor
Stephen A Charles
D Victor Perlroth
Li Song
Martin Linsell
Wayne To
Didier Benoit
James Aggen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kodiak Sciences Inc
Original Assignee
Kodiak Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kodiak Sciences Inc filed Critical Kodiak Sciences Inc
Application granted granted Critical
Publication of ES2819217T3 publication Critical patent/ES2819217T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F120/10—Esters
    • C08F120/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
    • C08F120/36—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate containing oxygen in addition to the carboxy oxygen, e.g. 2-N-morpholinoethyl (meth)acrylate or 2-isocyanatoethyl (meth)acrylate
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/3332—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing carboxamide group
    • C08G65/33324—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing carboxamide group acyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Graft Or Block Polymers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES14841835T 2013-09-08 2014-09-08 Conjugados de polímeros iónicos dipolares y factor VIII Active ES2819217T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361875099P 2013-09-08 2013-09-08
PCT/US2014/054622 WO2015035342A2 (en) 2013-09-08 2014-09-08 Factor viii zwitterionic polymer conjugates

Publications (1)

Publication Number Publication Date
ES2819217T3 true ES2819217T3 (es) 2021-04-15

Family

ID=52629093

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14841835T Active ES2819217T3 (es) 2013-09-08 2014-09-08 Conjugados de polímeros iónicos dipolares y factor VIII

Country Status (11)

Country Link
US (3) US10702608B2 (enExample)
EP (2) EP3041513B1 (enExample)
JP (5) JP6463361B2 (enExample)
DK (1) DK3041513T3 (enExample)
ES (1) ES2819217T3 (enExample)
HU (1) HUE052447T2 (enExample)
LT (1) LT3041513T (enExample)
PL (1) PL3041513T3 (enExample)
PT (1) PT3041513T (enExample)
SI (1) SI3041513T1 (enExample)
WO (1) WO2015035342A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
AU2018250695A1 (en) 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
US12469665B2 (en) 2021-10-19 2025-11-11 Hitachi High-Tech Corporation Charged particle beam device
WO2025184423A1 (en) * 2024-02-29 2025-09-04 Kodiak Sciences Inc. Cell-surface-targeting-domain-polymer-payload conjugate
WO2025190493A1 (de) 2024-03-15 2025-09-18 Alexander Wolf Pyrolyseanlage zum chargenweisen herstellen von pflanzenkohle durch pyrolyse von biomasse sowie verfahren

Family Cites Families (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5296363A (en) 1976-02-06 1977-08-12 Takamatsu Electric Works Ltd Device for supplementing gas in gas sealed distributing device
JPS5472168A (en) 1977-11-18 1979-06-09 Tiger Vacuum Bottle Ind Electric cooking implement
JPS5846044B2 (ja) 1979-04-14 1983-10-14 日本金属株式会社 圧粉鉄心
JPS5745009U (enExample) 1980-08-26 1982-03-12
JPS6337605Y2 (enExample) 1980-09-19 1988-10-05
JPS5846044U (ja) 1981-09-22 1983-03-28 桜井　幸雄 掘りごたつ
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
AU5772886A (en) 1985-04-12 1986-11-05 Genetics Institute Inc. Novel procoagulant proteins
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0584082B1 (en) 1991-01-31 2000-05-31 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
WO1993001221A1 (en) 1991-07-05 1993-01-21 Biocompatibles Limited Polymeric surface coatings
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5674545A (en) 1992-03-27 1997-10-07 Tidy Tea Limited Compressible packages for infusible substances
WO1993024640A2 (en) 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
WO1994007510A1 (en) 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
GB9301702D0 (en) 1993-01-28 1993-03-17 Biocompatibles Ltd New materials
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
GB9324033D0 (en) 1993-11-23 1994-01-12 Biocompatibles Ltd Ethylenically unsaturated compounds
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5681746A (en) 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US6541580B1 (en) 1995-03-31 2003-04-01 Carnegie Mellon University Atom or group transfer radical polymerization
US5763548A (en) 1995-03-31 1998-06-09 Carnegie-Mellon University (Co)polymers and a novel polymerization process based on atom (or group) transfer radical polymerization
GB9521234D0 (en) 1995-10-16 1995-12-20 Biocompatibles Ltd Synthesis of polymerisable phospho diesters
KR19990064280A (ko) 1995-10-16 1999-07-26 존 바드웰 인 함유 화합물의 산화방법
US5807937A (en) 1995-11-15 1998-09-15 Carnegie Mellon University Processes based on atom (or group) transfer radical polymerization and novel (co) polymers having useful structures and properties
US5663425A (en) 1996-01-26 1997-09-02 Lignotech Usa, Inc. Production of acid soluble humates
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5789487A (en) 1996-07-10 1998-08-04 Carnegie-Mellon University Preparation of novel homo- and copolymers using atom transfer radical polymerization
JPH10139832A (ja) 1996-11-08 1998-05-26 Nof Corp 共重合体およびグルコースセンサー
US7125938B2 (en) 1997-03-11 2006-10-24 Carnegie Mellon University Atom or group transfer radical polymerization
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
IL132240A0 (en) 1997-04-07 2001-03-19 Genentech Inc Anti-vegf antibodies
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
JP3052923B2 (ja) 1997-05-30 2000-06-19 日本油脂株式会社 （メタ）アクリレート誘導体の製造方法
US6555593B1 (en) 1998-01-30 2003-04-29 Albemarle Corporation Photopolymerization compositions including maleimides and processes for using the same
JP4162284B2 (ja) 1998-02-04 2008-10-08 日油株式会社 洗浄剤組成物
US6121371A (en) 1998-07-31 2000-09-19 Carnegie Mellon University Application of atom transfer radical polymerization to water-borne polymerization systems
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6159942A (en) 1998-06-19 2000-12-12 Bioenergy, Inc. Compositions for increasing energy in vivo
JP4145403B2 (ja) 1998-09-29 2008-09-03 日油株式会社 免疫学的活性物質測定用高分子／酵素結合体
US6384146B1 (en) 1999-04-05 2002-05-07 The Research Foundation Of State University Of New York Graft, graft-block, block-graft, and star-shaped copolymers and methods of making them
FR2794459B1 (fr) 1999-05-19 2004-09-03 Atofina Polyalcoxyamines issues de nitroxydes beta-substitues
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
ATE407697T1 (de) 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
US7049373B2 (en) 1999-08-06 2006-05-23 Carnegie Mellon University Process for preparation of graft polymers
US6803438B1 (en) 1999-09-08 2004-10-12 Polytherics Limited Uniform molecular weight polymers
US6348554B1 (en) 1999-11-30 2002-02-19 Rohmax Additives Gmbh Method for preparation of a liquid polymer composition and use of this composition
GB9928956D0 (en) 1999-12-07 2000-02-02 Malik Navid Internally supported biomimetic coating systems
AU2002211467A1 (en) 2000-10-06 2002-04-15 Carnegie-Mellon University Preparation of nanocomposite structures by controlled polymerization
DE60125409T2 (de) 2000-10-06 2007-09-27 Carnegie Mellon University Polymerisationsverfahren für ionische monomere
US6790919B2 (en) 2000-10-06 2004-09-14 Carnegie Mellon University Catalyst system for controlled polymerization
JP5049452B2 (ja) 2000-10-06 2012-10-17 バイオコンパティブルズ ユーケー リミテッド 両性イオン重合体
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
DE60236642D1 (de) 2001-04-06 2010-07-22 Univ Carnegie Mellon Verfahren zur herstellung von nanostrukturierten materialien
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6780428B2 (en) 2001-06-08 2004-08-24 Labopharm, Inc. Unimolecular polymeric micelles with an ionizable inner core
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
EP1421376A2 (de) 2001-08-27 2004-05-26 Zeptosens AG Bionalytische erkennungsoberfläche mit optimierter dichte der erkennungselemente
JP2003064132A (ja) 2001-08-28 2003-03-05 Nof Corp 重合体、製造方法および乳化・分散剤
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US6759491B2 (en) 2001-10-12 2004-07-06 Carnegie Mellon University Simultaneous reverse and normal initiation of ATRP
WO2003031480A2 (en) 2001-10-12 2003-04-17 Carnegie Mellon University Process for monomer sequence control in polymerizations
MXPA04004336A (es) 2001-11-07 2005-05-16 Nektar Therapeutics Al Corp Polimeros ramificados y sus conjugados.
US8048408B2 (en) 2002-01-16 2011-11-01 Biocompatibles Uk Limited Polymer conjugates
US20050220880A1 (en) 2002-03-07 2005-10-06 Lewis Andrew L Drug carriers comprising amphiphilic block copolymers
AU2003217009A1 (en) 2002-03-07 2003-09-16 Biocompatibles Uk Limited Compositions of polymers
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7196142B2 (en) 2002-04-04 2007-03-27 The University Of Akron Polyisobutylene-based block anionomers and cationomers and synthesis thereof
JP4248189B2 (ja) 2002-04-09 2009-04-02 株式会社資生堂 ホスホリルコリン基含有多糖類及びその製造方法
AU2003241531A1 (en) 2002-05-21 2003-12-12 Emory University Multivalent polymers with chain-terminating binding groups
EP1534764B1 (en) 2002-08-09 2014-07-16 Carnegie Mellon University Polymers, supersoft elastomers and methods for preparing the same
JP4431498B2 (ja) 2002-09-25 2010-03-17 バイオコンパティブルズ ユーケー リミテッド 動物投与用ポリマー組成物
US7737237B2 (en) 2002-11-07 2010-06-15 Phodia Chimie Controlled structure copolymer comprising an amphoteric or zwitterionic part
US20070111279A1 (en) 2002-11-13 2007-05-17 Procell, Inc. Production of recombinant therapeutic bioscavengers against chemical and biological agents
GB0301014D0 (en) 2003-01-16 2003-02-19 Biocompatibles Ltd Conjugation reactions
US20060167230A1 (en) 2003-01-20 2006-07-27 Takaki Koga Anti-pci neutralizing antibody
EP2267049A1 (en) 2003-02-05 2010-12-29 Biocompatibles UK Limited Block copolymers
AU2004210679A1 (en) 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
BRPI0409322B8 (pt) 2003-04-11 2021-05-25 Antriabio Inc método para preparar um conjugado de insulina-polímero
ES2725808T3 (es) 2003-05-23 2019-09-27 Nektar Therapeutics Derivados de PEG que contienen dos cadenas de PEG
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
CN1208358C (zh) 2003-07-31 2005-06-29 上海交通大学 含多羟基官能团多臂星状超支化聚合物刷及其制备方法
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
CN1852740B (zh) 2003-09-17 2011-05-11 耐科塔医药公司 多支链聚合物的药物前体
WO2005047337A1 (en) 2003-11-13 2005-05-26 Hanmi Pharmaceutical Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
HRP20140361T1 (hr) 2003-12-16 2014-05-23 Nektar Therapeutics Monodisperzne smjese pegiliranog naloksola
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
KR100593443B1 (ko) 2004-02-11 2006-06-28 삼성전자주식회사 트랜지스터들 및 그 제조방법들
JP4727938B2 (ja) 2004-02-24 2011-07-20 泰彦 岩崎 リビングラジカル重合開始基を持つポリリン酸の製造方法および用途
ATE507240T1 (de) 2004-03-05 2011-05-15 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
JP4727941B2 (ja) 2004-03-12 2011-07-20 泰彦 岩崎 生分解性重合体の製造方法および用途
US20050208093A1 (en) 2004-03-22 2005-09-22 Thierry Glauser Phosphoryl choline coating compositions
GB0412181D0 (en) * 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US7863238B2 (en) 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
KR101468345B1 (ko) 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
US7214759B2 (en) 2004-11-24 2007-05-08 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same
WO2006063055A2 (en) 2004-12-06 2006-06-15 Bolder Biotechnology, Inc. Enzyme conjugates for use as detoxifying agents
US20060257396A1 (en) 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
DE602005001922T2 (de) 2004-12-18 2007-12-06 Haldor Topsoe A/S Verfahren zur Regelung der Zugabe eines Reduktionsmittels in das Abgas einer Brennkraftmaschine
AR054428A1 (es) 2005-03-08 2007-06-27 Pharmacia & Upjohn Co Llc Composiciones de anticuerpos anti factor estimulante de colonia de macrofagos (anti-m-csf) que tienen menores niveles de endotoxina
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
EP1874844A4 (en) 2005-04-29 2010-03-24 Agency Science Tech & Res HYPER BRANCHED POLYMERS AND ITS APPLICATIONS
US20070005130A1 (en) 2005-06-29 2007-01-04 Thierry Glauser Biodegradable polymer for coating
WO2008020827A2 (en) 2005-08-01 2008-02-21 Biogen Idec Ma Inc. Altered polypeptides, immunoconjugates thereof, and methods related thereto
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
DE602006017416D1 (de) 2005-08-26 2010-11-18 Univ Carnegie Mellon Polymerisationsverfahren mit katalysatorreaktivierung
EP2364735A3 (en) 2005-12-16 2012-04-11 Nektar Therapeutics Branched PEG conjugates of GLP-1
US7906134B2 (en) 2005-12-21 2011-03-15 Abbott Laboratories Room temperature-curable polymers
DE102006009004A1 (de) 2006-02-23 2007-09-06 Sustech Gmbh & Co. Kg Multifunktionelle sternförmige Präpolymere, deren Herstellung und Verwendung
EP1988910B1 (en) 2006-02-28 2017-12-06 Kodiak Sciences Inc. Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
JP2007263935A (ja) 2006-03-30 2007-10-11 Canon Inc 磁性マーカー及びその製造方法
JP2009533519A (ja) 2006-04-14 2009-09-17 インターフェース バイオロジクス，インコーポレーテッド グラフトポリマーおよびその使用
JP5030036B2 (ja) 2006-05-23 2012-09-19 一彦 石原 生体成分固定化ポリマー組成物および三次元架橋体
EP2230264B1 (en) 2006-06-29 2019-10-09 Life Technologies AS Particles containing multi-block polymers
US20080008736A1 (en) 2006-07-06 2008-01-10 Thierry Glauser Random copolymers of methacrylates and acrylates
US8252878B2 (en) 2006-07-14 2012-08-28 Biocompatibles Uk Limited Polymer
KR100808116B1 (ko) 2006-08-22 2008-03-03 전남대학교산학협력단 미생물 점착 방지용 공중합체 수지 코팅재
ES2531934T3 (es) 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Glicoproteínas modificadas
JP5111016B2 (ja) 2006-11-01 2012-12-26 三井化学株式会社 表面親水性ポリオレフィン成形体およびその製造方法
WO2008064058A2 (en) 2006-11-21 2008-05-29 Abbott Laboratories Use of a terpolymer of tetrafluoroethylene, hexafluoropropylene, and vinylidene fluoride in drug eluting coatings
DK2099823T4 (da) 2006-12-01 2022-05-09 Seagen Inc Målbindingsmiddelvarianter og anvendelser deraf
US7651527B2 (en) 2006-12-15 2010-01-26 Medtronic Vascular, Inc. Bioresorbable stent
WO2008086395A2 (en) 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
EP2125016A2 (en) 2007-02-01 2009-12-02 Genetech, Inc. Combination therapy with angiogenesis inhibitors
WO2008098930A1 (en) 2007-02-14 2008-08-21 Biocompatibes Uk Limited Derivatisation of biological molecules
US8598364B2 (en) 2007-03-12 2013-12-03 Nektar Therapeutics Oligomer-protease inhibitor conjugates
JP5383514B2 (ja) 2007-03-12 2014-01-08 ウェルズ ファーゴ バンク ナショナル アソシエイション オリゴマー−抗ヒスタミン複合体
CN101053681B (zh) 2007-04-10 2010-05-19 天津大学 用于血管栓塞材料的温敏性MPC-b-NIPAM二嵌段星型共聚物及制备方法和应用
CA2682390A1 (en) 2007-04-17 2008-10-30 Imclone Llc Pdgfr.beta.-specific inhibitors
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
CA2684153A1 (en) 2007-05-14 2008-11-27 Tyco Healthcare Group Lp Furanone copolymers
JP5019524B2 (ja) 2007-06-01 2012-09-05 国立大学法人 東京大学 新規ポリ（メタ）アクリレート共重合体ならびに小胞体及びゴルジ体への送達方法
JP5351889B2 (ja) 2007-06-21 2013-11-27 テクニシェ ユニバーシタット ミュンヘン インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質
JP2009042617A (ja) 2007-08-10 2009-02-26 Canon Inc 静電荷像現像用トナー及びその製造方法
US7943370B2 (en) 2007-08-23 2011-05-17 Canon Kabushiki Kaisha Structure, target substance detection element and target substance detection kit
AU2008312457B2 (en) 2007-10-19 2014-04-17 Genentech, Inc. Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
AU2008314697B2 (en) 2007-10-22 2013-08-29 Merck Serono S.A. Single IFN-beta fused to a mutated lgG Fc fragment
JP2009114283A (ja) 2007-11-05 2009-05-28 Asahi Kasei Chemicals Corp 吸引用シートおよびそれを用いた装置
US20110059176A1 (en) 2007-11-22 2011-03-10 The University Of Tokyo Material for preventing tissue adhesion and material for preventing joint contracture
ES2613963T3 (es) 2008-01-18 2017-05-29 Medimmune, Llc Anticuerpos manipulados con cisteína para conjugación específica de sitio
JP5344420B2 (ja) 2008-05-15 2013-11-20 独立行政法人国立循環器病研究センター 遺伝子導入剤及びその製造方法並びに核酸複合体
US9732142B2 (en) 2008-05-15 2017-08-15 Biocompatibles Uk Limited Intracellular antibody delivery
US8187623B2 (en) 2008-06-25 2012-05-29 Boston Scientific Scimed, Inc. Medical copolymers
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
JP2010117189A (ja) 2008-11-12 2010-05-27 Sumitomo Bakelite Co Ltd 生理活性物質固定化用基板
US8802738B2 (en) 2008-12-12 2014-08-12 University Of Massachusetts Polyesters with grafted zwitterions
US8822610B2 (en) 2008-12-22 2014-09-02 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US20100158850A1 (en) 2008-12-23 2010-06-24 The Regents Of The University Of Michigan Dendrimer based modular platforms
WO2010111625A1 (en) 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
EP3165606A1 (en) 2009-05-01 2017-05-10 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
CN101575402B (zh) 2009-05-31 2012-06-27 中国科学院化学研究所 一种多臂星型聚合物及其制备方法
DK2260873T3 (da) 2009-06-08 2019-09-16 Biocompatibles Uk Ltd Pcylering af proteiner
BRPI1012321A8 (pt) 2009-06-17 2016-09-27 Abbott Biotherapeutics Corp Anticorpos anti-vegf e seus usos
CA2766405A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc Engineered fc regions for site-specific conjugation
CN102025901A (zh) 2009-09-23 2011-04-20 国基电子（上海）有限公司 相机模组及其检测方法
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
WO2011066417A2 (en) 2009-11-24 2011-06-03 Carnegie Mellon University Antibodies and conjugates for modulators of angiogenesis
TWI505836B (zh) 2009-12-11 2015-11-01 Genentech Inc 抗－ｖｅｇｆ－ｃ抗體及其使用方法
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
JP5914363B2 (ja) 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
US9493543B2 (en) 2010-02-16 2016-11-15 Novo Nordisk A/S Factor VIII fusion protein
ES2742216T3 (es) 2010-04-15 2020-02-13 Kodiak Sciences Inc Polímeros que contienen zwitteriones de alto peso molecular
JP2012025820A (ja) 2010-07-21 2012-02-09 Kansai Paint Co Ltd 親水化処理剤組成物
KR101380009B1 (ko) 2011-01-17 2014-04-02 주식회사 엘지화학 신규한 화합물 및 이를 포함하는 유기 발광 소자
WO2012145746A1 (en) 2011-04-21 2012-10-26 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of neuromyelitis optica
WO2013040501A1 (en) 2011-09-16 2013-03-21 Pharmathene, Inc. Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
WO2013059137A1 (en) * 2011-10-17 2013-04-25 Oligasis High molecular weight zwitterion-containing polymers
EP3539982B1 (en) 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
JP6244350B2 (ja) 2012-04-03 2017-12-06 ノーベルメッド セラピューティクス インコーポレイテッド． ヒト化およびキメラ抗因子Ｂｂ抗体、ならびにその使用
JP5846044B2 (ja) 2012-05-23 2016-01-20 日油株式会社 （メタ）アクリル酸誘導体の製造方法
JP6234064B2 (ja) 2012-05-23 2017-11-22 キヤノン株式会社 重合体、前記重合体を用いた核磁気共鳴分析用または磁気共鳴イメージング用の造影剤、化合物、前記重合体を用いた核磁気共鳴分析方法および磁気共鳴イメージング方法
JP2015532307A (ja) 2012-10-15 2015-11-09 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 凝固因子ｖｉｉポリペプチド
SI2968461T1 (sl) 2013-03-13 2023-01-31 Genzyme Corporation Fuzijski proteini, ki vsebujejo vezavna dela PDGF in VEGF in postopek njihove uporabe
CN103193819A (zh) 2013-03-13 2013-07-10 苏州蔻美新材料有限公司 一锅法合成mpc的方法
SG10201708143QA (en) 2013-06-06 2017-11-29 Pf Medicament Anti-c10orf54 antibodies and uses thereof
CN103421039B (zh) 2013-09-03 2015-12-23 重庆工商大学 2-甲基丙烯酰氧基乙基磷酰胆碱的合成方法
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
MX379491B (es) 2014-06-28 2025-03-10 Kodiak Sciences Inc Antagonistas duales de factor de crecimiento derivado de plaquetas (pdgf)/factor de crecimiento endotelial vascular (vegf)
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
AU2018250695A1 (en) 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
US20240209076A1 (en) 2020-05-08 2024-06-27 Kodiak Sciences Inc. Use of il-6 antibodies and vegf traps, and fusion constructs and conjugates thereof
US20240238427A1 (en) 2021-04-14 2024-07-18 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3251000A1 (en) 2022-02-10 2023-08-17 Kodiak Sciences Inc. METHODS FOR PURIFYING A PRODUCT

Also Published As

Publication number Publication date
US20230173081A1 (en) 2023-06-08
DK3041513T3 (da) 2020-10-26
EP3760639B1 (en) 2025-10-22
JP6732056B2 (ja) 2020-07-29
WO2015035342A2 (en) 2015-03-12
US20160199501A1 (en) 2016-07-14
WO2015035342A3 (en) 2015-04-30
JP2020183404A (ja) 2020-11-12
PL3041513T3 (pl) 2021-01-25
JP7767260B2 (ja) 2025-11-11
PT3041513T (pt) 2020-09-07
HUE052447T2 (hu) 2021-04-28
SI3041513T1 (sl) 2020-11-30
EP3760639C0 (en) 2025-10-22
US20200261590A1 (en) 2020-08-20
JP2023029851A (ja) 2023-03-07
EP3760639A1 (en) 2021-01-06
JP2019081765A (ja) 2019-05-30
JP7232796B2 (ja) 2023-03-03
JP2016530302A (ja) 2016-09-29
EP3041513A4 (en) 2017-04-12
JP6463361B2 (ja) 2019-01-30
US10702608B2 (en) 2020-07-07
US12214044B2 (en) 2025-02-04
LT3041513T (lt) 2020-11-25
US11590235B2 (en) 2023-02-28
EP3041513B1 (en) 2020-08-05
JP2025165944A (ja) 2025-11-05
EP3041513A2 (en) 2016-07-13

Similar Documents

Publication Publication Date Title
US12214044B2 (en) Factor VIII zwitterionic polymer conjugates
ES2623677T3 (es) Forma de sal de un producto conjugado de polímero-fármaco multibrazo
ES2875426T3 (es) Compuestos de hormona de crecimiento humana recombinante pegilada
JP5687752B2 (ja) オリゴマー−プロテアーゼ阻害剤複合体
ES2536450T3 (es) Conjugados que tienen una unión degradable y reactivos poliméricos útiles en la preparación de tales conjugados
ES2242396T3 (es) Conjugados de analogos de peg-lhrh.
ES2947818T3 (es) Nuevos profármacos poliméricos de la HCh
US10413614B2 (en) Conjugates for protection from nephrotoxic active substances
WO2011042450A1 (en) Carrier linked paliperidone prodrugs
JP2019521107A (ja) ヒトグルカゴン及び統計上のコポリアミノ酸を含む注射用溶液の形態の組成物
KR20160075665A (ko) 소마토스타틴 및 그 유사체의 컨쥬게이트
CN109589415B (zh) 一种聚乙二醇-多肽和蛋白类药物的结合物
US20250313579A1 (en) Ligand compounds comprising a chelating group as a bridging group
TW200426155A (en) Activated polyethylene glycol esters
HK40043414A (en) Zwitterionic polymer conjugates
HK40043412A (en) Zwitterionic polymer conjugates
BR112024008991B1 (pt) Conjugado de derivado de poli(e-l-lisina)-fármaco, e, composto
BR112018011152B1 (pt) Agonistas de cnp de liberação controlada